The practical aspects of combination therapy with angiotensin receptor blockers and angiotensin-converting enzyme inhibitors

JRAAS - Journal of the Renin-Angiotensin-Aldosterone System

Volumn 3, Issue 2, 2002, Pages 66-71

  Sica, Domenic A ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

ACE inhibitors; Angiotensin II; Angiotensin receptor blockers; Combination therapy; Congestive heart failure; Hypertension; Nephropathy

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; BENAZEPRIL; CANDESARTAN HEXETIL; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; EPROSARTAN; LISINOPRIL; LOSARTAN; RAMIPRIL; TELMISARTAN; TRANSFORMING GROWTH FACTOR BETA1; VALSARTAN; ANGIOTENSIN RECEPTOR;

ANTIHYPERTENSIVE ACTIVITY; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG CLASSIFICATION; DRUG EFFICACY; HUMAN; HYPERTENSION; KIDNEY DISEASE; PRESCRIPTION; PROTEINURIA; REVIEW; TREATMENT OUTCOME; DRUG ANTAGONISM; DRUG COMBINATION;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; DRUG THERAPY, COMBINATION; HEART FAILURE, CONGESTIVE; HUMANS; HYPERTENSION; KIDNEY DISEASES; RECEPTORS, ANGIOTENSIN;

EID: 0036615537     PISSN: 14703203     EISSN: None     Source Type: Journal    
DOI: 10.3317/jraas.2002.020     Document Type: Review

References (61)

1. Therapeutic trials comparing angiotensin converting enzyme inhibitors and angiotensin II receptor blockers
2. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy
3. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes
4. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy
5. Renal protective effects of enalapril in hypertensive NIDDM: Role of baseline albuminuria
6. Progression, remission, regression of chronic renal disease
7. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients
8. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): A randomised trial against atenolol
9. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): A randomised trial against atenolol
10. Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure
11. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure
12. Efficacy and tolerability of candesartan cilexetil monotherapy or in combination with other antihypertensive drugs. Results of the AURA study
13. Additive effects of losartan and enalapril on blood pressure and plasma active renin
14. Pilot study of combined blockade of the renin-angiotensin system in essential hypertensive patients
15. Efficacy of candesartan cilexetil as add-on therapy in hypertensive patients uncontrolled on background therapy: A clinical experience trial. ACTION Study Investigators
16. Additive hypotensive effect of angiotensin-converting enzyme inhibition and angiotensin-receptor antagonism in essential hypertension
17. Combination therapy with an angiotensin converting enzyme inhibitor and an angiotensin-II receptor antagonist for refractory essential hypertension
18. Low doses of ACE inhibitors and AT1 blockers have a synergistic effect but high doses are less than additive
19. Reduction of proteinuria; combined effects of receptor blockade and low dose angiotensin-converting enzyme inhibition
20. Add-on angiotensin II receptor blockade lowers urinary transforming growth factor-beta levels
21. Add-on angiotensin receptor blockade with maximized ACE inhibition
22. ACEI/ATRA therapy decreases proteinuria by improving glomerular permselectivity in IgA nephritis
23. Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: The candesartan and lisinopril microalbuminuria (CALM) study
24. Additive antiproteinuric effect of a converting-enzyme inhibitor and losartan in normotensive patients with IgA nephropathy
25. Coadministration of losartan and enalapril exerts additive antiproteinuric effect in IgA nephropathy
26. IgA nephropathy and inhibitors of the renin angiotensin system: Is reduction in proteinuria adequate proof of efficacy?
27. Safety of the combination of valsartan and benazepril in patients with chronic renal disease
28. Angiotensin converting enzyme inhibitors and angiotensin receptor (AT1) antagonists: Either or both for primary renal disease?
29. Combination ACE inhibitor and angiotensin II receptor antagonist therapy in diabetic nephropathy
30. Additive antiproteinuric effect of combined ACE inhibition and angiotensin II receptor blockade
31. Combined therapy with an angiotensin II receptor blocker and an angiotensin-converting enzyme inhibitor in heart failure
32. Angiotensin-II receptor blockade further reduces afterload safely in patients maximally treated with angiotensin-converting enzyme inhibitors in heart failure
33. Is there a place for combining angiotensin-converting enzyme inhibitors and angiotensin-receptor antagonists in the treatment of hypertension, renal disease or congestive heart failure?
34. Comparison of candesartan, enalapril, and their combination in congestive heart failure. Randomized Evaluation of Strategies for Left Ventricular Dysfunction (RESOLVD) pilot study
35. Synergistic efficacy of enalapril and losartan on exercise performance and oxygen consumption at peak exercise in congestive heart failure
36. Augmented short- and long-term hemodynamic and hormonal effects of an angiotensin receptor blocker added to angiotensin converting enzyme inhibitor therapy in patients with heart failure
37. ADEPT: Addition of the AT1 receptor antagonist eprosartan to ACE inhibitor therapy in chronic heart failure trial: Hemodynamic and neurohormonal effects
38. The Randomized Angiotensin receptor Antagonist - ACE inhibitor Study (RAAS) - Pilot study
39. Angiotensin II receptor blockade combined to ACE-inhibition improves left ventricular dilation and exercise ejection fraction in congestive heart failure
40. Addition of angiotensin II receptor blockade to maximal angiotensin-converting enzyme inhibition improves exercise capacity in patients with severe congestive heart failure
41. A study of the efficacy and safety of irbesartan in combination with conventional therapy, including ACE inhibitors, in heart failure
42. 1-antagonist eprosartan
43. Pharmacology and clinical efficacy of angiotensin-receptor blockers
44. Angiotensin-converting enzyme inhibitors
45. Persistent formation of angiotensin II despite treatment with maximally recommended doses of angiotensin converting enzyme inhibitors in patients with chronic heart failure
46. Therapeutic implications of escape from angiotensin-converting enzyme inhibition in patients with chronic heart failure
47. Antihypertensive therapy with MK 421: Angiotensin II-renin relationships to evaluate efficacy of converting enzyme blockade
48. Effect of combining an ACE inhibitor and an angiotensin II receptor blocker on plasma and kidney tissue angiotensin II levels
49. Angiotensin II formation from ACE and chymase in human and animal hearts: Methods and species considerations
50. Angiotensin converting enzyme and non-ACE dependent angiotensin II generation in resistance arteries from patients with heart failure and coronary heart disease
51. Upregulation of angiotensin-converting enzyme during the healing process after injury at the site of percutaneous transluminal coronary angioplasty in humans
52. T-lymphocyte and plasma angiotensin-converting enzyme activity during enalapril and losartan administration in humans
53. Long-term effects of angiotensin-converting enzyme inhibition and metabolic control in hypertensive type 2 diabetic patients
54. Effect of bradykinin-receptor blockade on the response to angiotensin-converting-enzyme inhibitor in normotensive and hypertensive subjects
55. Angiotensin-converting enzyme inhibition potentiates angiotensin II type 1-receptor effects on renal bradykinin and cGMP
56. From the HOPE to the ONTARGET and the TRANSCEND studies: Challenges in improving prognosis
57. Maximally recommended doses of angiotensin-converting enzyme (ACE) inhibitors do not completely prevent ACE-mediated formation of angiotensin II in chronic heart failure
58. Valsartan in acute myocardial infarction trial (VALIANT): Rationale and design
59. Candesartan in heart failure - Assessment of reduction in mortality and morbidity (CHARM): Rationale and design
60. Effect of combining an ACE inhibitor and an angiotensin II receptor blocker on plasma and kidney tissue angiotensin II levels
61. Effects of enalapril and eprosartan on the renal vascular nitric oxide system in human essential hypertension